Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL14745544

CCc1cc(C(=O)O)c(=O)[nH]c1-c1ccc(N2C[C@H]3C[C@@H](NC)C[C@H]3C2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.33
PARP2 Q9UGN5 1/20 0.33
CHRNB2 P17787 4/20 0.32
CHRNA4 P43681 4/20 0.32
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
HRH4 Q9H3N8 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
MAOA P21397 1/20 0.31
MAOB P27338 1/20 0.31
KCNH2 Q12809 1/20 0.30
CACNA1B Q00975 1/20 0.30
TOP1 P11387 1/20 0.30
MCHR1 Q99705 1/20 0.30
RBP4 P02753 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL14745542 1.00 PARP1 (0.33) PARP1PARP2CHRNB2CHRNA4PDE3B
Trifluoroacetic Acid SCHEMBL16568516 1.00 PARP1 (0.33) PARP1PARP2CHRNB2CHRNA4PDE3B
SCHEMBL17594885 0.95 PARP1 (0.35) PARP1PARP2PDE3BPDE3AKCNH2
SCHEMBL16577238 0.95 PARP1 (0.35) PARP1PARP2PDE3BPDE3AKCNH2
SCHEMBL17594883 0.95 PARP1 (0.35) PARP1PARP2PDE3BPDE3AKCNH2
SCHEMBL14745545 0.87 PDE3B (0.32) PARP1PARP2PDE3BPDE3ACACNA1B
Trifluoroacetic Acid SCHEMBL14741141 0.85 CACNA1B (0.38) PARP1PARP2PDE3BPDE3ACACNA1B
SCHEMBL16568089 0.83 PARP1 (0.35) PARP1PARP2PDE3BPDE3AKCNH2
Trifluoroacetic Acid SCHEMBL14745505 0.83 KDM4E (0.33) CHRNB2CHRNA4KCNH2
Hydrochloric Acid SCHEMBL14745655 0.83 PARP1 (0.34) PARP1PARP2PDE3BPDE3AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016039936-A2 MONOCYCLIC SUBSTITUTED 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS PTC THERAPEUTICS, INC. (US) 2016-03-17 WO claimed
US-20150080362-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-03-19 US claimed
US-9650395-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2017-05-16 US disclosed
US-20150080362-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-03-19 US disclosed
EP-2750505-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033240-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150080362-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP PARP1 2143/4885PARP2 2251/4885CHRNB2 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.